Hester Biosciences Limited — Updates, 30-01-2025: Press Release

Hester Biosciences has reported mixed performance in its latest financial results for Q3 and the nine-month period ending December 2024. Standalone revenues for Q3 decreased by 4% to ₹628.26 million, while nine-month revenues increased by 14% to ₹2,097.94 million. The Animal Healthcare Division experienced a significant drop of 24% in Q3 due to seasonal factors, a reduction in milk prices impacting farmer spending, and a product recall. Conversely, the Poultry Healthcare Division posted strong growth, with Q3 sales up by 12%, driven by rising demand for vaccines against prevalent diseases. The Petcare Division saw remarkable growth of 105% in Q3, highlighting its potential.

Consolidated results revealed a significant profit surge, with Q3 PAT up by 184% and nine-month PAT up by 85%. This growth reflects improved operational efficiencies and market demand, particularly in exports from subsidiaries in Nepal and Africa. Looking forward, Hester aims to bolster its bottom line and market presence, with upcoming product launches expected to further enhance growth, particularly in the Poultry Healthcare segment. Overall, investors should monitor Hester's recovery trajectory and potential for growth in its key divisions.